Arcturus Therapeutics

Arcturus Therapeutics San Diego Office Headquarters

Allen JavanpourIntern, RNA Production

Allen Javanpour, Intern, RNA Production

Angel LeuSenior Research Associate, Frontier Science

Angel Leu, Senior Research Associate, Frontier Science

Arisa Iga CaleResearch Associate I, RNA Production

Arisa Iga Cale, Research Associate I, RNA Production

Banibrata (Bani) GhoshSenior Research Associate, Analytical

Banibrata (Bani) Ghosh, Senior Research Associate, Analytical

Bijan GodarziResearch Associate I, Frontier Science

Bijan Godarzi, Research Associate I, Frontier Science

Carina WimerResearch Associate II, Drug Discovery

Carina Wimer, Research Associate II, Drug Discovery

Carlos Perez-GarciaSenior Scientist, Drug Discovery

Carlos Perez-Garcia, Senior Scientist, Drug Discovery

Cheryl ChanIntern, Analytical Development

Cheryl Chan, Intern, Analytical Development

Christine (Christy) EsauVice President of Research and Development

Christine Esau joined Arcturus in 2015 and serves as Vice President of Research and Development. She most recently served as Arcturus’ Senior Director of Translational Research. Dr. Esau was previously lead biologist at Ionis Pharmaceuticals and Regulus Therapeutics and served as Chief Scientific Officer of AptamiR Therapeutics. She has performed pioneering work in microRNA biology and anti-miRNA targeting technology development, resulting in landmark, highly cited papers and early patent filings. As lead biologist for the anti-miR-122 program for treatment of HCV with Regulus, she moved the program from discovery biology to lead compound selection, directing pharmacology, PK/PD, safety, and mechanism of action studies. At Regulus, she led exploratory efforts to identify novel microRNA targets for metabolic diseases, in the process establishing an extensive network of academic collaborators. Dr. Esau led the anti-miR-33 program for atherosclerosis which came out of these efforts and was the basis for Regulus’ partnership with Astra-Zeneca. While Chief Scientific Officer of AptamiR Therapeutics, Dr. Esau worked to develop a microRNA based therapy for the treatment of obesity. Dr. Esau earned a B.S. degree in biology from the California Institute of Technology and a Ph.D. from the Massachusetts Institute of Technology.

Christine (Christy) Esau, Vice President of Research and Development

Christopher GaviganIntern, Frontier Science

Christopher Gavigan, Intern, Frontier Science

Daiki MatsudaSenior Scientist, Frontier Science

Daiki Matsuda, Senior Scientist, Frontier Science

Daniel HwangSenior Staff Accountant

Daniel Hwang, Senior Staff Accountant

Flora HuynhSenior Research Associate, Analytical/Lab Coordinator

Flora Huynh, Senior Research Associate, Analytical/Lab Coordinator

Hanyi (Han) ChangResearch Associate I, Formulation Development

Hanyi (Han) Chang, Research Associate I, Formulation Development

Hari BhaskaranScientist I, Transnational Biology

Hari Bhaskaran, Scientist I, Transnational Biology

Hazel SantosAccounts Payable Specialist

Hazel Santos, Accounts Payable Specialist

Inna KoukharevaSenior Manager, Analytical Development

Inna Koukhareva, Senior Manager, Analytical Development

Jae Heon (Jay) KimIntern, Formulation Development

Jae Heon (Jay) Kim, Intern, Formulation Development

Jared DavisDirector, RNA Process Development

Jared Davis, Director, RNA Process Development

Jenny ParkScientist I, RNA Sciences

Jenny Park, Scientist I, RNA Sciences

Jerel VegaSenior Research Associate, Formulation Development

Jerel Vega, Senior Research Associate, Formulation Development

Jennifer PerkinsExecutive Assistant

Jennifer Perkins, Executive Assistant

Jocelyn OngFront Desk Coordinator/Administrative Assistant I

Jocelyn Ong, Front Desk Coordinator/Administrative Assistant I

Jonathan BushResearch Associate I, Formulation Development

Jonathan Bush, Research Associate I, Formulation Development

KC KummerfeldSenior Director, Finance & Corporate Controller

KC Kummerfeld, Senior Director, Finance & Corporate Controller

Manual (Manny) JuarezFacilities, Shipping/Receiving Coordinator

Manual (Manny) Juarez, Facilities, Shipping/Receiving Coordinator

Rebecque LabaVice President of Finance & Operations

Rebecque Laba joined Arcturus in August 2017 and serves as Vice President of Finance and Operations. Ms. Laba was previously Vice President, Finance and Corporate Operations at Celladon Corporation where she led the company through a successful IPO and raised over $100MM in private equity and debt. Prior to Celladon Ms. Laba served as Senior Director, Finance and Administration at Idun Pharmaceuticals which was acquired by Pfizer in 2005. Ms. Laba has over 18 years of experience in the life sciences and over 25 years of experience in finance and operations.

Rebecque Laba, Vice President of Finance & Operations

Kiyoshi TachikawaSenior Research Fellow

Kiyoshi Tachikawa, Senior Research Fellow

Kim McAdenPurchasing Manager

Kim McAden, Purchasing Manager

Lena CeballosSenior Research Associate, Analytical Development

Lena Ceballos, Senior Research Associate, Analytical Development

Lishuang (Lily) XuResearch Associate II, Drug Discovery

Lishuang (Lily) Xu, Research Associate II, Drug Discovery

Maher AlayyoubiScientist II, RNA Process Development

Maher Alayyoubi, Scientist II, RNA Process Development

Marciano SabladScientist II, Translational Biology

Marciano Sablad, Scientist II, Translational Biology

Michael (Mike) CuddyResearch Associate III, Drug Discovery

Michael (Mike) Cuddy, Research Associate III, Drug Discovery

Michelle NguyenResearch Associate I, Analytical Development

Michelle Nguyen, Research Associate I, Analytical Development

Mike MatsumotoResearch Associate I, Drug Discovery

Mike Matsumoto, Research Associate I, Drug Discovery

Pad ChivukulaScientific Advisor

Dr. Chivukula previously served as Chief Scientific Officer and Chief Operating Officer of Arcturus Therapeutics Ltd. and was formerly on Arcturus’ Board since March 2013. Prior to Arcturus, from June 2008 until February 2013, Dr. Chivukula was employed by Nitto Denko Corporation, where his titles included Group Leader and Chief Scientist, and where he led the polymeric RNAi research department. Dr. Chivukula's background includes over 15 years of experience in drug delivery and therapeutic drug development at Nitto Denko Corporation and the University of Utah. Dr. Chivukula has a Ph.D. in Pharmaceutical Chemistry from the University of Utah where he specialized in lipid-mediated delivery systems and technology.

Pad Chivukula, Scientific Advisor

Parsa ParirokhResearch Associate I, RNA Process Development

Parsa Parirokh, Research Associate I, RNA Process Development

Pattraranee (Patty) LimphongSenior Manager, RNA Process Development

Pattraranee (Patty) Limphong, Senior Manager, RNA Process Development

Priya KarmaliSr. Director, Pharmaceutical Development

Priya Karmali is Senior Director of Pharmaceutical Development at Arcturus Therapeutics Ltd. Dr. Karmali joined Arcturus in 2015 and is responsible for research and development efforts for LUNAR™ technology, Arcturus’ lipid mediated nucleic acid delivery system. She has over 15 years of experience in the field of lipid-based drug delivery systems from discovery to development. Prior to Arcturus, Priya was Associate Director of Formulation Development at Regulus Therapeutics where she led drug product development efforts for miRNA therapeutic drugs currently in various stages of clinical trials. Prior to joining Regulus, Priya was a Principal Scientist at Nitto Denko where she led formulation development efforts for their Vitamin A targeted siRNA lipid nanoparticle for treatment of liver fibrosis. Dr. Karmali has a Ph.D. in Chemistry from the Indian Institute of Chemical Technology where she specialized in development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She is an author or inventor on over 35 scientific publications and patents.

Priya Karmali, Sr. Director, Pharmaceutical Development

Rajesh MukthavaramScientist I, Formulation Development

Rajesh Mukthavaram, Scientist I, Formulation Development

Ramon Diaz TrellesScientist II, Frontier Science

Ramon Diaz Trelles, Scientist II, Frontier Science

Robin LeeSenior Research Associate, Formulation Development

Robin Lee, Senior Research Associate, Formulation Development

Samuel LeeResearch Associate I, RNA Process Development

Samuel Lee, Research Associate I, RNA Process Development

Samantha MurphyAssociate Director, Business Development

Samantha Murphy, Associate Director, Business Development

Scott RobertsSenior Manager, CMC

Scott Roberts, Senior Manager, CMC

Sharon LeeResearch Associate I, Frontier Science

Sharon Lee, Research Associate I, Frontier Science

Mark HerbertInterim President

Mark R. Herbert is Interim President of Arcturus Therapeutics Ltd. Mr. Herbert joined Arcturus in 2015, and previously served as Vice President of Business Development and Alliance Management. He previously was Head of U.S. Business Development and Sales at STA Pharmaceutical Co., Ltd., WuXi AppTec’s small molecule development and manufacturing division, where he was responsible for all North American business development and marketing activities. Prior to WuXi AppTec, Mr. Herbert served as Director of Pharmaceutical Sciences at Aragon Pharmaceuticals, Inc. which was acquired by Johnson & Johnson in 2013.

Mark Herbert, Interim President

Wendy TaylorDirector, Project Management

Wendy Taylor, Director, Project Management

Steven LyResearch Associate I, Analytical Development

Steven Ly, Research Associate I, Analytical Development

Nancy FuselliDirector, Quality & Regulatory Affairs

Nancy Fuselli, Director, Quality & Regulatory Affairs

Stuart CollinsonExecutive Chair of the Board

Stuart Collinson, Executive Chair of the Board

ThanhChau DamResearch Associate II, Translational Biology

ThanhChau Dam, Research Associate II, Translational Biology

Thu LeIntern, Formulation Development

Thu Le, Intern, Formulation Development

Tran TrinhResearch Associate I, RNA Process Development

Tran Trinh, Research Associate I, RNA Process Development

Kumar RajappanPrincipal Scientist, Chemistry

Kumar Rajappan, Principal Scientist, Chemistry

Jose GonzalezResearch Associate I, Translational Biology

Jose Gonzalez, Research Associate I, Translational Biology

Xuequn (Helen) HuaAssociate Director, Translational Biology

Xuequn (Helen) Hua, Associate Director, Translational Biology

Yanjie (Belle) BaoScientist II, Formulation Development

Yanjie (Belle) Bao, Scientist II, Formulation Development

Yi KuoIntern, RNA Production

Yi Kuo, Intern, RNA Production

Adam PavlicekBioinformatics Consultant

Adam Pavlicek, Bioinformatics Consultant

Carol HidalgoHuman Resources Consultant

Carol Hidalgo, Human Resources Consultant

Michael HodgesR&D & Medical Consultant

Michael Hodges, R&D & Medical Consultant

Steve TanisChemistry Consultant

Steve Tanis, Chemistry Consultant

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA chemistry and delivery technologies.

News & Events